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Effects of spironolactone on systolic blood pressure in diabetic the kidney has been recognized to be important in the
rats. regulation of glucocorticoid-induced disorders of electro-
Background. Mineralocorticoid hormones, which maintain lyte balance and in the control of blood pressure [1–3].electrolyte balance and blood pressure, are thought to be asso-
Two distinct forms of 11b-HSD isozymes exhibit dehydro-ciated not only with the expression of renal 11b-hydroxysteroid
dehydrogenase type 2 (11b-HSD2), but also with that of intra- genase activities of renal 11b-HSD: a low-affinity NADP1-
cellular mineralocorticoid receptors (MRs). The present study dependent 11b-HSD1 and a high-affinity NAD1-depen-
was designed to test whether the mineralocorticoid action of dent 11b-HSD2 [4, 5]. Analysis of the gene structures
glucocorticoid corticosterone on renal MR is involved in the
has demonstrated that the two enzymes are products ofdevelopment of diabetes-associated hypertension by measur-
separate genes, and that the expression of these isozymeing the alterations of renal 11b-HSD2.
Method. We measured the mean systolic blood pressure, genes has highly tissue-specific patterns [6, 7]. In particu-
renal 11b-HSD1, and mRNA levels in streptozotocin (STZ)- lar, the biological function of renal 11b-HSD2 has been
induced diabetic rats that received spironolactone, insulin, or suggested to provide a protective mechanism that pre-no treatment, and in nondiabetic controls that received spiro-
vents glucocorticoids from binding to renal MR, and thusnolactone.
Results. Four weeks after an injection of STZ, the renal 11b- it regulates renal sodium balance and blood pressure.
HSD2 and mRNA levels were significantly lower in diabetic Impairment of renal 11b-HSD2 has been shown to allow
rats than in control rats, and the mean systolic blood pressure corticosterone activation of renal MR, which causes cor-was 14.8% higher in diabetic rats than in controls. Subcutane-
ticosterone to act as a mineralocorticoid to induce bloodous injections of spironolactone into diabetic rats for three
weeks partially reversed the decrease in renal 11b-HSD2 activ- pressure elevation [8–11]. These observations indicate
ity and gene expression, and prevented the mean systolic blood that a relationship exists between the alteration of 11b-
pressure elevation. Spironolactone treatment for one week also HSD2 and the action of MR and blood pressure.resulted in a significant reduction in mean systolic blood pres-
Mineralocorticoid receptors in kidney tissue are wellsure during the development of diabetic hypertension. How-
ever, treatment with STZ did not significantly decrease the known to be colocalized with renal 11b-HSD2 and to
renal 11b-HSD1 activity and mRNA expression, and spirono- play an important role in the regulation of blood pressure
lactone treatment did not exert a significant effect on this [5, 12, 13]. Inhibition of kidney 11b-HSD2–induced bloodenzyme in STZ-induced diabetic rats.
pressure elevation has been shown to be associated withConclusion. In the development of diabetes-induced hyper-
tension, the effect of spironolactone on mean systolic blood the activation of MR, which can be blocked by a specific
pressure may be associated with the mineralocorticoid effects MR antagonist [14, 15]. Importantly, the actions of the
of corticosterone on renal MR, as well as an alteration of specific MR antagonist spironolactone not only preventrenal 11b-HSD2 activity and its mRNA expression in insulin-
the activation of renal MR [16], but also interfere withdependent diabetic rats.
the metabolism of several microsomal cytochrome P-450s
and inhibit the biosynthesis of adrenocortical steroids
[17, 18], such as corticosterone or cortisol, which areThe presence of 11b-hydroxysteroid dehydrogenase
(11b-HSD) and mineralocorticoid receptors (MRs) in associated with blood pressure and 11b-HSD isozymes
[19, 20]. However, little is known about the contribution
of spironolactone-associated alteration of the renal 11b-Key words: 11b-hydroxysteroid dehydrogenase, blood pressure, miner-
alocorticoid receptor, diabetes mellitus, IDDM. HSD isozyme in the regulation of blood pressure through
its influence on corticosterone metabolism.Received for publication January 4, 1999
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tion has been speculated to play an important role in the injection of aldosterone 20 mg/kg per day for three weeks.
The systolic blood pressure of all animals was deter-development of diabetic hypertension [21, 22]. However,
the mechanism responsible for blood pressure elevation mined weekly by tail-cuff plethysmography. At the end
of the fourth week after STZ injection, the mean arterialis still incompletely understood, although hyperglyce-
mia-elevated levels of circulating corticosterone or corti- pressure of diabetic rats was also measured using a pres-
sure transducer, as reported previously [31]. Animalssol might contribute to the presence of complications
in insulin-dependent diabetes mellitus [23, 24]. Plasma were anesthetized and killed four weeks after the admin-
istration of STZ or sesame oil. The doses of STZ, insulin,aldosterone levels are usually low, and are accompanied
by adrenal zona glomerulosa impairment in insulin- spironolactone, and aldosterone and the treatment regi-
men were similar to those previously described by otherdependent diabetes mellitus [25–27]. Recently, experi-
mental diabetes studies have shown that hyperglycemia investigators [30, 32, 33].
induces a reduction in the intracellular NAD1/NADH
Measurement of blood glucose, insulin, aldosterone,ratio [28, 29], which possibly contributes to an alteration
and corticosteroneof the NAD1-dependent 11b-HSD2 enzyme. We reported
that diabetic hypertension was associated with decreased The glucose concentration was measured using a glu-
cose oxidase system. Serum insulin was measured byrenal 11b-HSD2 gene expression [30]. However, it is
unclear whether the corticosterone occupancy of renal double-antibody radioimmunoassay (RIA) using rat in-
sulin as a standard [27]. Plasma aldosterone and cortico-MR is involved in the pathogenesis of diabetes-associ-
ated hypertension or how experimental diabetes in rats sterone were determined by RIA.
following treatment with an MR antagonist leads to al-
Enzyme activity assayterations of the renal 11b-HSD isozyme. In the present
study, we examined the effects of the MR antagonist The dehydrogenase activities of the renal 11b-HSD1
and 11b-HSD2 isozymes were measured by determiningspironolactone on systolic blood pressure and dehydro-
genase activities of the renal 11b-HSD isozyme, as well the conversion of [3H]corticosterone (B) to [3H]11-dehy-
drocorticosterone (A), as previously reported [30, 34,as 11b-HSD gene expression in streptozotocin (STZ)-
induced, insulin-dependent diabetic male rats. 35]. Briefly, kidney tissues (0.5 g) were homogenized in
Krebs-Ringer buffer solution at 48C in a Dounce tissue
grinder. Tissue homogenates were centrifuged, and the
METHODS
protein concentration of the supernatants was deter-
Animals and treatment mined in a homogenate dilution by the method of Brad-
ford (Bio-Rad protein assay kit; Bio-Rad, Hercules, CA,Eight-week-old male Sprague-Dawley rats were pur-
chased from the Charles River Laboratories (Shizuoka, USA). The homogenate supernatants were diluted ap-
propriately to yield consistent protein concentrationsJapan). The animals were maintained on standard chow
and water ad libitum under normal 12-hour light/dark and were incubated with 2 mmol/L [3H]B (specific activ-
ity, 90 Ci/mmol; New England Nuclear Corp., Danvers,cycles (light on between 7 a.m. and 7 p.m.), with an
ambient temperature range of 22 to 268C. Diabetes was MA, USA) and 3.4 mmol/L NADP1 as a cofactor (for
11b-HSD1 activity in kidney) or 100 nmol/L [3H]B andinduced by a single tail vein injection of STZ (65 mg/kg;
Wako Pure Chemical Industries, Osaka, Japan) in a 0.01 200 mmmol/L NAD1 as a cofactor (for 11b-HSD2 activ-
ity in kidney) at 378C for 10 minutes in an agitated bath.mol/L citrate buffer, pH 4.0. Nondiabetic control rats
were injected with an equal volume of citrate buffer. Preliminary studies established an adjustment of the pro-
tein concentration to ensure the linearity of product for-After three days, the induction of diabetes was confirmed
by measurement of blood glucose concentrations and mation over a 12-minute incubation period. Steroids
were extracted with ethyl acetate and were separated byinsulin levels. One week after the administration of STZ,
the diabetic rats were randomly divided into diabetes, thin-layer chromatography in a chloroform-ethanol (9:1)
system. The conversion of [3H]B to [3H]A was calculateddiabetes 1 spironolactone, and diabetes 1 insulin groups.
A subcutaneous injection of spironolactone 50 mg/kg from the radioactivity of each fraction.
per day (dissolved in sesame oil) was administered to
RNA preparation and Northern blot assaydiabetic and normal rats beginning one or three weeks
after the STZ injection, and continuing until the end of Total RNA was extracted from kidney samples by the
modified acid guanidinium thiocyanate phenol chloro-four weeks after the diabetes induction. Control rats
received an injection of sesame oil alone. Rats in the form method described previously [30, 36]. For Northern
blotting, aliquots of total RNA (20 mg) were electropho-diabetes 1 insulin group were given a subcutaneous in-
jection of insulin (Sigma Chemical Co., St. Louis, MO, resed on 1.4% agarose gels and transferred to a nylon
membrane (Hybond-N1; Amersham, Tokyo, Japan) byUSA) at a dose of 12.5 IU/kg body wt twice a day for
three weeks. Some normal rats received a subcutaneous capillary transfer. To assist in the quantitation of the
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Table 1. Blood glucose, serum insulin, plasma corticosterone, and aldosterone levels in the different groups of animals
Plasma Plasma
Blood glucose Serum insulin corticosterone aldosterone
Group N mmol/L pmol/L lg/dL ng/dL
Normal 6 7.8160.61 6765.8 11.363.7 26.265.2
Normal 1 SP 6 7.6160.62 6366.7 10.262.1 27.963.3
Diabetic 5 3062.5a 2062.6a 22.863.3b 1664.3c
Diabetic 1 SP 6 25.963.1a 20.462.8a 13.562.7d 13.663.7b
Diabetic 1 I 6 7.8562.8 70.266.1 10.864.6 23.965.1
All values are mean 6 SEM. Abbreviations are: SP, spironolactone; I, insulin.
aP , 0.001 vs. normal rats
bP , 0.01 vs. normal rats
cP , 0.05 vs. normal rats
dP , 0.05 vs. untreated diabetic rats
mRNA levels, hybridization was performed in identical
buffers containing radiolabeled probes for 11b-HSD.
The cDNAs encoding rat 11b-HSD1 (1265 bp) and 11b-
HSD2 (1864 bp) were kindly provided by Dr. White and
Dr. Gomez-Sanchez, respectively [11, 37]. Rat cDNA
probes for 11b-HSD1 and 11b-HSD2 were labeled with
[32P] GTP (specific activity 6000 Ci/mmol; Amersham
International, Bucks, UK) using nick translation (Nick
Translation System; BRL Life Technologies, Inc., Tokyo,
Japan). For densitometric measurements, autoradio-
graphic signals were standardized to signals determined
from 18S rRNA in each preparation to control for the
amount of RNA loaded per lane.
Statistical analysis Fig. 1. Changes in systolic blood pressure in normal male rats (m),
normal male rats treated with spironolactone (j), streptozotocin (STZ)-All data are expressed as the mean 6 SEM. Differ-
induced diabetic male rats (s), and STZ-induced diabetic male ratsences between groups were evaluated by analysis of vari- treated with insulin (d). Each point represents the mean 6 SEM (N 5 6
ance (ANOVA), followed by the Student–Newman– rats per group). #P , 0.05 compared with normal control male rats;
*P , 0.05 compared with untreated STZ-induced diabetic male rats;Keuls multiple comparisons test to assess statistical
##P , 0.01 compared with normal control male rats; **P , 0.01 com-significances. A value of P , 0.05 was considered statisti- pared with untreated STZ-induced diabetic male rats.
cally significant.
RESULTS in blood glucose levels, but the decrease in this group
Table 1 shows the blood glucose, insulin, corticoste- was not significantly different from that in untreated
rone, and aldosterone values in the different groups of diabetic rats. Moreover, spironolactone administration
animals. The blood glucose levels of STZ-induced dia- to normal rats did not exert any significant effect on
betic rats were significantly higher than those of normal the blood glucose, insulin, aldosterone, or corticosterone
rats (P , 0.01). STZ-treated rats had significantly lower levels. Treatment of diabetic rats with insulin for three
levels of serum insulin than those of nondiabetic rats weeks completely reversed the changes in the levels of
(P , 0.01). The plasma corticosterone level in STZ- blood glucose, insulin, aldosterone, and corticosterone
induced diabetic rats was significantly higher than that (Table 1).
in control rats (P , 0.01). STZ-treated rats had lower Figure 1 shows changes in the mean systolic blood
levels of plasma aldosterone than those of normal rats pressure levels during four weeks after the injection of
(P , 0.05). Administration of spironolactone for three STZ. In the first week after the STZ treatment, the sys-
weeks restored the corticosterone levels in diabetic rats tolic blood pressure was 7% higher than that of the
to approximately the normal range. The serum insulin control; however, the mean systolic blood pressure in
and plasma aldosterone levels in the diabetic groups did diabetic rats was not statistically significantly higher than
not change significantly compared with levels in un- that in the controls. However, systolic blood pressure in
treated diabetic rats. Treatment of diabetic rats with diabetic rats two weeks after STZ treatment was signifi-
cantly higher than that of the controls (136 6 1 vs. 126 6spironolactone for three weeks induced a slight decrease
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Fig. 3. Renal 11b-HSD1 dehydrogenase levels in normal male rats (N,
N 5 6), STZ-induced diabetic male rats (D, N 5 5), and STZ-induced
diabetic male rats treated with spironolactone (D 1 SP, N 5 6). The
enzyme activity is expressed as percentage conversion of [3H] corticoste-
rone (B) to [3H] 11-dehydrocorticosterone (A). Values are mean 6
SEM. NS is no significant difference.Fig. 2. Effects of spironolactone on systolic blood pressure in STZ-
induced diabetic male rats treated with spironolactone once daily by
subcutaneous injection. Spironolactone treatment was initiated one or
three weeks after injection of STZ. Symbols are: ( ) normal male
rats 1 vehicle; (s) STZ-induced diabetic male rats; (d) STZ-in-
duced diabetic male rats 1 spironolactone (for 3 weeks); (m) STZ-
induced diabetic male rats 1 spironolactone (for 1 week). Values are
mean 6 SEM from six rats. *P , 0.05 compared with untreated STZ-
induced diabetic male rats; **P , 0.01 compared with untreated
STZ-induced diabetic male rats; #P , 0.05 compared with normal
control male rats; ##P , 0.01 compared with normal rats.
1 mm Hg, P , 0.05). In the third and four weeks, the
systolic blood pressure values of the diabetic rats were
elevated even further, from 144 6 2 to 149 6 2 mm Hg.
At the end of four weeks after STZ treatment, the mean
arterial pressure measured directly through the carotid
artery also showed a significant increase in the experi-
mental diabetic group (108 6 8.3 vs. 137 6 15.5 mm Hg,
P , 0.05). STZ-induced diabetic rats treated with insulin
Fig. 4. Northern blot hybridization of 11b-HSD1 cDNA and 18S
maintained blood pressure levels similar to those of the rDNA probes shows mRNA expression (A) and relative quantitation
of 11b-HSD1 mRNA levels (B) in kidneys of normal males (N, N 5control nondiabetic rats (Fig. 1). There were no signifi-
6), STZ-induced diabetic males (D, N 5 5), and STZ-induced diabeticcant differences in blood pressure levels between con-
male rats treated with spironolactone (D 1 SP, N 5 6). (A) Two 11b-
trols and normal rats treated with spironolactone for HSD1 mRNA species are shown (approximate sizes 1.4 and 1.7 kb).
(B) Values are shown as mean (6 SEM) of the ratio of 11b-HSD1/18Speriods ranging from one to three weeks (Fig. 1).
mRNA levels. NS is no significant difference.The effects of spironolactone on the mean systolic
blood pressure of diabetic rats are shown in Figure 2.
Treatment with spironolactone for three weeks signifi-
cantly mediated the elevation in blood pressure level in diabetic rats and normal rats (41 6 1.9 vs. 39.5 6 1.6%).
diabetic rats compared with untreated diabetic rats (P , Similarly, there was no significant difference in renal 11b-
0.01). However, during the three weeks of spironolac- HSD1 mRNA levels between diabetic rats and normal
tone treatment, the systolic blood pressure levels in the controls (Fig. 4). An injection of spironolactone into
treatment groups were not significantly different from diabetic rats for three weeks did not result in significantly
those in the normal control group. Moreover, three higher renal 11b-HSD1 activity than that found in un-
weeks after the STZ-induced diabetic rats received spiro- treated diabetic rats. In parallel, treatment of diabetic
nolactone for one week only, the elevated blood pressure rats with spironolactone produced a slight increase in
in diabetes was significantly reduced to 128 6 2 mm Hg, the renal 11b-HSD1 mRNA levels, but renal 11b-HSD1
a level similar to that in the normal rats. gene expression in this group was not significantly
Alterations of renal 11b-HSD1 activity in the diabetic greater than that in nondiabetic rats (Fig. 4).
rats are shown in Figure 3. There was no significant differ- As shown in Figure 5, the administration of STZ to
rats significantly decreased renal 11b-HSD2 activity toence in renal 11b-HSD1 activity between STZ-induced
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fects of renal 11b-HSD2 in controlling glucocorticoid-
induced sodium retention and hypertension are medi-
ated by MRs. Impairment of renal 11b-HSD2, as seen in
congenital disorders such as apparent mineralocorticoid
excess (AME) and in subjects treated with carbenoxo-
lone (CBX) or 11a-hydroxyprogesterone (11a-OHP),
leads to increased binding of corticosterone or cortisol
to MR, ultimately causing sodium retention and hyper-
tension. Treatment with spironolactone is known to be
effective because it blocks MRs, and it has been used for
the treatment of hypertension associated with apparent
mineralocorticoid excess (AME) [38]. Recent experi-Fig. 5. 11b-HSD2 levels in normal male rat kidneys (N, N 5 6), normal
male rats treated with spironolactone (N 1 SP, N 5 6), STZ-induced ments have also shown that the hypertensinogenic effects
diabetic male rats (D, N 5 5), STZ-induced diabetic male rats treated of carbenoxolone (CBX) and 11a-hydroxyprogesteronewith spironolactone (D 1 SP, N 5 6), and STZ-induced diabetic male
(11a-OHP) are inhibited by the specific MR antagonistrats treated with insulin (D 1 I, N 5 6). Enzyme activity is expressed
as percentage conversion of [3H] corticosterone (B) to [3H] 11-dehydro- RU 28318 [14, 15]. These studies demonstrated that the
corticosterone (A). Values are mean 6 SEM (N 5 rats per group). impairment of renal 11b-HSD2 causing hypertension is*P , 0.01 compared with normal male rats; **P , 0.01 compared with
also associated with a glucocorticoid-dependent mineral-untreated STZ-induced diabetic male rats.
ocorticoid action by the occupancy of MRs.
In experimental diabetes mellitus, an increase in plas-
ma corticosterone levels has been well demonstrated
33% less than that of age-matched normal rats (21.1 6 and might contribute to the rise in blood pressure. The
1.9 vs. 31.7 6 2.5%, P , 0.01); this decrease in enzyme mechanism responsible for this abnormal corticosterone
activity was paralleled by significantly lower levels of elevation is thought to be associated with hyperglycemia
renal 11b-HSD2 mRNA expression in STZ-induced dia- and activation of the hypothalamic-pituitary-adrenal axis
betic rats than in normal rats (P , 0.01; Figs. 6 and [25, 39, 40]. In the present study, our results indicate that
7). A subcutaneous injection of spironolactone into the diabetic rats had a markedly increased concentration of
diabetic rats for three weeks, however, markedly in- plasma corticosterone, and decreased renal 11b-HSD2
creased the renal 11b-HSD2 activity to 23% more than activity and mRNA expression, and that these changes
that of untreated diabetic rats (P , 0.05), but did not were associated with elevated systolic blood pressure
restore it to normal levels (Fig. 5). Similarly, treatment and mean arterial pressure in male rats in which diabetes
of diabetic rats with spironolactone significantly in- was induced by STZ. Plasma aldosterone levels were
creased the levels of renal 11b-HSD2 mRNA expression lower in STZ-induced diabetes. Treatment of diabetic
to 31% more than that of untreated diabetic rats (P , rats with the MR antagonist spironolactone decreased
0.01). However, spironolactone administration to normal plasma corticosterone levels and prevented the develop-
rats for three weeks did not exert any significant effect ment of diabetic hypertension. Moreover, three weeks
on the renal 11b-HSD2 activity or mRNA levels. A sub- after STZ treatment, the hypertension produced by dia-
cutaneous injection of insulin into the diabetic rats for betes was markedly reduced by administration of spiro-
three weeks markedly increased renal 11b-HSD2 activity nolactone to block the MR. These results demonstrate
compared with activity in untreated diabetic rats (P , that corticosterone activation of renal MR is associated
0.01; Fig. 5); however, the level in this insulin-treated with the development of diabetic hypertension in STZ-
group was not significantly different than that in normal induced diabetes. The discovery of the mineralocorticoid
action of corticosterone expressed at the site of the renalrats. In parallel, treatment of diabetic rats with insulin
MR explains why, with the renal 11b-HSD2 enzymecompletely restored renal 11b-HSD2 gene expression to
inhibition in STZ-induced diabetes, the renal distal tu-the normal range. Aldosterone treatment of normal rats
bule is exposed to large quantities of unmetabolized cor-for three weeks did not significantly affect renal 11b-
ticosterone, which results in a glucocorticoid-dependentHSD2 activity or mRNA expression (data not shown).
occupancy of MR and thus induces renal sodium reten-
tion and blood pressure elevation.
DISCUSSION Mineralocorticoid receptors are present not only in
It is well accepted that the mineralocorticoid action the kidney, but also in other mineralocorticoid target
of glucocorticoid hormones in kidney tissues is depen- tissues including the brain, vasculature, and heart. In
dent not only on the presence of renal 11b-HSD2 activ- particular, the central nervous system expresses a higher
ity, but also on the activation of renal MRs. Several density of MRs than other mineralocorticoid target tis-
sues, and is thought to be important in the maintenancestudies have also demonstrated that the action and ef-
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Fig. 6. Northern blot shows 11b-HSD2 mRNA expression in kidneys of normal male rats (N, N 5 6), normal male rats treated with spironolactone
(N 1 SP, N 5 6), STZ-induced diabetic male rats (D, N 5 5), STZ-induced diabetic male rats treated with spironolactone (D 1 SP, N 5 6), and
STZ-induced diabetic male rats treated with insulin (D 1 I, N 5 6). (A) A single 11b-HSD2 mRNA band of approximately 1.9 kb. (B) Hybridization
to 18S mRNA.
diabetes. In addition, decreased renal 11b-HSD2 activity
can enhance the renal vasoconstrictor potency of cortico-
sterone, which may also be associated with blood pres-
sure elevation in STZ-induced diabetes.
It is now well known that spironolactone, which struc-
turally resembles aldosterone, acts as a competitive an-
tagonist of mineralocorticoids on the distal tubules of
kidney. The action of spironolactone in controlling blood
pressure is considered to be due to its ability to bind to
renal MRs and to prevent the binding of excess mineralo-
Fig. 7. Relative quantitation of 11b-HSD2 mRNA levels in normal corticoids or glucocorticoid-dependent mineralocorti-
male rats (N), normal male rats treated with spironolactone (N 1 SP), coids [16], which are implicated in the pathogenesis ofSTZ-induced diabetic male rats (D), STZ-induced diabetic male rats
hypertension. Moreover, spironolactone may directlytreated with spironolactone (D 1 SP), and STZ-induced diabetic male
rats treated with insulin (D 1 I). Values are mean (6 SEM) of ratio mediate adrenal microsomal cytochrome P-450 to de-
of 11b-HSD2/18S mRNA levels (N 5 6 rats per group). *P , 0.01 crease the adrenocortical function and inhibit the adre-compared with normal male rats; **P , 0.01 compared with untreated
nal secretion of mineralocorticoid or glucocorticoidSTZ-induced diabetic male rats.
hormones [17, 18], all of which can contribute to the
reduction of diabetic hypertension. In the present study,
our results indicate that STZ-induced diabetes elevates
of normal blood pressure and the development of miner- blood pressure and decreases renal 11b-HSD2 activity
alocorticoid-induced hypertension [41–43]. Because MRs and gene expression. Spironolactone administered to di-
are inherently nonselective, these receptors in the brain abetic rats partially reversed the decrease in renal 11b-
tissue can be activated equally by mineralocorticoid or HSD2 activity and mRNA expression, and relieved the
glucocorticoid hormones or blocked by the MR antago- elevation in blood pressure in the development of diabe-
nist spironolactone. Recently, a number of studies have tes-related hypertensive rats. These results indicate that
shown that the central administration of 11b-HSD inhib- the effects of spironolactone on diabetic hypertension is
itors or mineralocorticoids to rats can induce hyperten- mediated, at least in part, through changes in renal 11b-
sion by the activation of MR [15, 44]. Similarly, the HSD2 activity and gene expression. The data also sup-
central blockade of MR by mineralocorticoid antagonist port the hypothesis that the role of spironolactone on
RU 28318 was reported to reduce blood pressure in rats blood pressure is not necessarily limited to its binding
[45]. Furthermore, experimental diabetes studies have to MR, but may also be associated with alterations of
shown that increased sympathetic activity is associated renal 11b-HSD2 in diabetic rats. Interestingly, a recent
with diabetic hypertension in insulin-dependent diabetes study has reported that the hypertensinogenic properties
mellitus. Thus, the possibility that a MR action in the of 11b-HSD2 inhibitors did not act solely through MRs
brain is involved in the development of diabetic hyper- [14], although the hypertensinogenic effects of these sub-
tension must also be considered, or at least that the pre- stances were blocked by MR antagonists.
ventative effect of spironolactone on MRs in brain tissues In our study, although diabetes markedly decreased
renal 11b-HSD2 activity and mRNA levels and elevatedcontributes to a blood pressure reduction in STZ-induced
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blood pressure of STZ-induced diabetic rats, there was ert its antihypertensive effect on diabetes-associated hy-
no marked reduction of either renal 11b-HSD1 activity pertension not only through competitive binding to MRs,
or gene expression in STZ-induced diabetes. Spironolac- but also through an increase increase, at least partly, in
tone treatment partially reversed the decrease in the renal 11b-HSD2 activity and gene expression of STZ-
expression of renal 11b-HSD2 enzyme and reduced induced diabetic rats.
blood pressure in diabetes; however, it did not signifi-
cantly affect renal 11b-HSD1 activity and mRNA expres- ACKNOWLEDGMENTS
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